Clinical Validity of Bayley-4: Comparison of Clinical Groups & Matched Controls

  • at -
  • at

This webinar will explain specific areas of function that are delayed and intervention strategies appropriate for at least three of the clinical groups described in the Bayley-4 validity studies.

Presented by: Glen P. Aylward, Ph.D., ABPP

A primary purpose of the Bayley-4 is to identify infants and toddlers who have delays in development. One way to verify the validity of the new test for this purpose is to compare children from at-risk groups to matched controls to determine if there are differences in scores. Infants and toddlers from specifically defined risk groups were included in the Bayley-4 validity studies (for example: children with Autism Spectrum Disorder; Language Delay; Developmental Delay; Motor Impairment; Prenatal Drug/Alcohol Exposure; Moderately or Late Preterm (32-36 weeks); and Extremely or Very Preterm (<32 weeks)). Children from these risk groups were compared on all the Bayley-4 subscales.

Learner Outcomes

Based on the content of the webinar, participants will be able to:

  1. Describe the rationale for the inclusion of the clinical validity studies in Bayley-4.
  2. List at least three clinical groups included in the clinical validity studies for Bayley-4.
  3. Explain specific areas of function that are delayed and intervention strategies appropriate for at least three of the clinical groups described in the Bayley-4 validity studies.

Time-ordered Agenda - Eastern Time Zone

11:00 to 11:10pm  The rationale for clinical validity studies completed as part of the development of Bayley-4

11:10 to 11:50 pm  Comparison of clinical groups with matched control groups using Bayley-4. Including: Down Syndrome, Autism Spectrum Disorder, Language Delay, Specific Language Impairment, Developmental Delay, Motor Impairment, Prenatal Drug/Alcohol Exposure, Extremely or Very Preterm.

11:50 to 12:00 pm  Question & Answer Session